The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | CD79b-specific CAR T-cell therapy: overcoming treatment resistance in B-cell lymphoma
Here, Sattva Neelapu, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the utilization of CD79b-specific CAR T-cells for targeting CAR T-cell therapy resistance due to loss of CD19 in B-cell lymphomas. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA., Prof. Neelapu reveals the preclinical results that suggest targeting CD79b could be a novel strategy to overcome this resistance.
